Flag of the European Union EU Clinical Trials Register Help

Clinical trials for T2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    573 result(s) found for: T2. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001823-38 Sponsor Protocol Number: IMS-267 Start Date*: 2013-08-05
    Sponsor Name:National Institute of Public Health and Environment (RIVM, the Netherlands)
    Full Title: Second meningococcal vaccination in Dutch children: Study to compare the tetravalent MenACWY-TT conjugate vaccine with the monovalent MenC-TT conjugate vaccine.
    Medical condition: The monovalent MenC-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal group C. The tetravelent MenACWY-TT vaccin administered in this study is used to...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003230-22 Sponsor Protocol Number: CICL670AIT07 Start Date*: 2008-11-04
    Sponsor Name:NOVARTIS FARMA
    Full Title: Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent β-thalassemic patients with cardiac MRI ...
    Medical condition: cardiac iron overload
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019024 Haemosiderosis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002474-13 Sponsor Protocol Number: 3.199 Start Date*: 2017-04-24
    Sponsor Name:Innovatiefonds Zorgverzekeraars
    Full Title: Medication Optimization for ADHD: MOVA study Implementation and evaluation of double-blind placebo-controlled titration in clinical practice
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003690-65 Sponsor Protocol Number: 78304 Start Date*: 2021-11-10
    Sponsor Name:St Antonius Hospital
    Full Title: Peppermint Oil for the treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT study
    Medical condition: Irritable Bowel syndrome Functional Abdominal Pain Not otherwise specified
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002176-27 Sponsor Protocol Number: HC-G-H-1505 Start Date*: 2017-08-30
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: Pragmatic, prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of a 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution ...
    Medical condition: Hypovolaemia due to acute blood loss in trauma surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10021137 Hypovolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) NL (Completed) ES (Restarted) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-021499-27 Sponsor Protocol Number: Kreussler-Dynexan® Mundgel-0410 Start Date*: 2010-09-13
    Sponsor Name:Chemische Fabrik Kreussler & Co. GmbH
    Full Title: A Prospective, Randomized, Multi-centre, Placebo-controlled, Double blind, Comparative Study To Evaluate the Efficacy and Safety of Dynexan® Mundgel in Subjects with Acute Teething Pain
    Medical condition: Teething in babies which can lead to symptoms like irritability, rash, and severe pain.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052001 Teething pain LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021062-29 Sponsor Protocol Number: CICL670A2214 Start Date*: 2010-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe c...
    Medical condition: transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10065974 Chronic iron overload LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001967-58 Sponsor Protocol Number: 253MS201 Start Date*: 2020-11-20
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizu...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003086-40 Sponsor Protocol Number: PIX001 Start Date*: 2008-04-08
    Sponsor Name:Fondation Charcot Stichting
    Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)
    Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020538-24 Sponsor Protocol Number: GASAS-1002X Start Date*: 2011-02-16
    Sponsor Name:GABA International AG
    Full Title: White spot lesion development in post-orthodontic patients following weekly application of a 1.25% fluoride gel compared to placebo over 6 months
    Medical condition: To monitor the white spot lesion development and dental status under weekly applied 1.25% fluoride gel compared to placebo in patients after orthodontic treatment with multibracket appliances
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015319-41 Sponsor Protocol Number: TSO-MS Start Date*: 2011-11-03
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS)
    Medical condition: remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002009-37 Sponsor Protocol Number: 0517 Start Date*: 2017-07-14
    Sponsor Name:Neuroanæstesiologisk Klinik, RH/Glostrup
    Full Title: "The effect of Betamethasone gel and NSAID gel lubricated on the laryngeal mask on pain in the throat, hoarseness and cough after anesthesia. "
    Medical condition: 'Healthy volunteers' (sore throat, hoarseness and cough, consumption of analgesics, postoperative itching, numbness and burning sensation from the throat)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002162-30 Sponsor Protocol Number: HC-G-H-1504 Start Date*: 2017-04-12
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: Prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in patients u...
    Medical condition: Hypovolaemia due to acute blood loss in elective abdominal surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10021137 Hypovolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) ES (Restarted) FR (Ongoing) AT (Completed) HR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005929-89 Sponsor Protocol Number: CLOU064C12302 Start Date*: 2022-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SI (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) HR (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005032-30 Sponsor Protocol Number: 2021-PDNO-003 Start Date*: 2022-05-16
    Sponsor Name:Attgeno AB
    Full Title: An open-label, multicenter study to evaluate the DOSE, efficacy, safety and tolerability of PDNO (Nitrosooxypropanol) infusion in patients with pulmonary hypertension after cardiopulmonary bypass (...
    Medical condition: Acute Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001947-70 Sponsor Protocol Number: MBP8298-RR-01 Start Date*: 2006-09-14
    Sponsor Name:BioMS Technology Corp.
    Full Title: A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003372-31 Sponsor Protocol Number: LJ401-BT01 Start Date*: 2018-03-20
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Multi-center, Randomized, Open-Label, Parallel-Group Study with LJPC-401 for the Treatment of Myocardial Iron Overload in Patients with Transfusion-Dependent Beta Thalassemia
    Medical condition: Transfusion-dependent beta thalassemia with myocardial iron overload
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CY (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003567-10 Sponsor Protocol Number: 217023 Start Date*: 2021-12-23
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS
    Full Title: A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonuc...
    Medical condition: Hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005899-36 Sponsor Protocol Number: CLOU064C12301 Start Date*: 2022-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001133-15 Sponsor Protocol Number: 19.4.208B Start Date*: 2005-09-08
    Sponsor Name:NV Organon
    Full Title: A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy, safety and pharmacokinetics of 4 doses of Org 25969 and placebo administered at reappear...
    Medical condition: Not applicable
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 21 08:50:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA